Engaging multiple receptors with bispecific biologics offers the potential to improve upon single-agent checkpoint blockade and promises to be the .. Read more next generation of immunotherapy. Cambridge Healthtech Institute’s Second Annual Bispecific Antibodies for Cancer Immunotherapy conference will showcase preclinical, translational and clinical studies on using bispecific antibodies for dual blockade of checkpoint targets, T-cell-redirecting bispecific biologics, overcoming T-cell exhaustion, as well as strategies to improve efficacy and reduce toxicity, and engineer the next generation of bi- and multi-specific biologics.
- [ Users who have shown interest for this Event ]
- + Add me as user
- Share your Experience
12 Aug 2020
More Events From The Organizer
- Accelerating Genomic Research ..23 Sep 2020Online